Skip to main content

Table 2 Clinical and demographic characteristics of the study participants.

From: Are exhaled nitric oxide measurements using the portable NIOX MINO repeatable?

 

Birth cohort participants*

 
 

All participants

Participants with asthma

Non-asthmatic participants

Intervention study participants

 

(n = 494)

(n = 71)

(n = 401)

(n = 65)

Age (years), mean (range)

17.17 (16-18)

17.21 (16-18)

17.16 (16-18)

11 (6-16)

Sex, no. (%)

    

   Male

251 (50.8)

36 (50.7)

207 (51.6)

38 (58.5)

   Female

243 (49.2)

35 (49.3)

194 (48.4)

27 (41.5)

Hay fever, no. (%)

183 (37.0)

49 (69.0)

125 (31.2)

56 (86.2)

Eczema, no. (%)

82 (16.6)

24 (33.8)

56 (14.0)

38 (58.5)

Atopy (as defined by skin prick testing), no. (%) **

195 (42.1)

48 (72.7)

141 (37.3)

37/42 (88.1)

FEV 1 (% predicted), mean (SD)

104.58 (13.22)

97.34 (15.38)

105.99 (12.28)

90.35 (14.57)

FeNO (ppb), median (interquartile range) ***

16 (11-31)

40 (16-74)

15 (11-25.5)

35 (13.5-57.0)

Asthma treatment, no. (%)

    

   Inhaled corticosteroids

NA

34 (47.9)

NA

65 (100)

   Short-acting bronchodilators

 

46 (64.8)

 

65 (100)

   Long-acting bronchodilators

 

12 (16.9)

 

48 (73.8)

   Montelukast

 

1 (1.4)

 

36 (55.4)

   Theophylline

 

0 (0)

 

3 (4.6)

  1. *Some of the birth cohort participants could not be categorised because not all questions were answered. NA: Not applicable.
  2. ** Percentages are based on the number of participants in whom skin prick testing was performed.
  3. *** Values are based on the first FeNO reading obtained in each participant.